|
MX2007014114A
(es)
|
2005-05-10 |
2008-03-14 |
Intermune Inc |
Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
|
|
EP2032578A2
(en)
*
|
2006-05-30 |
2009-03-11 |
Pfizer Products Incorporated |
Triazolopyridazine derivatives
|
|
WO2007147217A1
(en)
*
|
2006-06-22 |
2007-12-27 |
Prana Biotechnology Limited |
Method of treatment of glioma brain tumour
|
|
US8198448B2
(en)
|
2006-07-14 |
2012-06-12 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
US8217177B2
(en)
*
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
PE20080403A1
(es)
|
2006-07-14 |
2008-04-25 |
Amgen Inc |
Derivados heterociclicos fusionados y metodos de uso
|
|
EP2046336A4
(en)
*
|
2006-07-18 |
2010-12-15 |
Cytovia Inc |
3-ARYL-6-ARYL-7H- [1,2,4] TRIAZOLO [3,4-B] [1,3,4] THIADIAZINE AND ANALOGUE AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCTORS AND THEIR USE
|
|
JP2010500365A
(ja)
|
2006-08-07 |
2010-01-07 |
インサイト・コーポレイション |
キナーゼ阻害剤としてのトリアゾロトリアジン
|
|
WO2008036272A1
(en)
*
|
2006-09-18 |
2008-03-27 |
Vertex Pharmaceuticals Incorporated |
HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF
|
|
ES2560435T3
(es)
|
2006-11-22 |
2016-02-19 |
Incyte Holdings Corporation |
Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
|
|
EP2137162B1
(en)
*
|
2007-03-15 |
2018-08-01 |
Novartis AG |
Organic compounds and their uses
|
|
KR101156845B1
(ko)
*
|
2007-05-21 |
2012-06-18 |
에스지엑스 파마슈티컬스, 인코포레이티드 |
헤테로시클릭 키나제 조절제
|
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
|
WO2009005675A1
(en)
*
|
2007-06-28 |
2009-01-08 |
Abbott Laboratories |
Novel triazolopyridazines
|
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
PA8792501A1
(es)
*
|
2007-08-09 |
2009-04-23 |
Sanofi Aventis |
Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
|
|
FR2929613B1
(fr)
*
|
2008-04-02 |
2010-12-31 |
Sanofi Aventis |
Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met
|
|
FR2919870B1
(fr)
*
|
2007-08-09 |
2014-05-16 |
Sanofi Aventis |
Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet
|
|
EP2193133B1
(en)
|
2007-09-27 |
2015-08-19 |
Fundación Centro Nacional de Investigaciones Oncológicas Carlos III |
Imidazolothiadiazoles for use as protein kinase inhibitors
|
|
DE102007061963A1
(de)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
PE20091468A1
(es)
|
2008-02-28 |
2009-10-22 |
Novartis Ag |
DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
|
|
DE102008019907A1
(de)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
MX393622B
(es)
|
2008-05-21 |
2025-03-24 |
Incyte Corp |
Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas.
|
|
JP5627574B2
(ja)
|
2008-06-03 |
2014-11-19 |
インターミューン, インコーポレイテッド |
炎症性および線維性疾患を治療するための化合物および方法
|
|
DE102008028905A1
(de)
*
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
|
US20100041663A1
(en)
|
2008-07-18 |
2010-02-18 |
Novartis Ag |
Organic Compounds as Smo Inhibitors
|
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
|
UY32049A
(es)
|
2008-08-14 |
2010-03-26 |
Takeda Pharmaceutical |
Inhibidores de cmet
|
|
DE102008038222A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
Indazol-5-carbonsäurehydrazid-derivate
|
|
DE102008038221A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-Azaindolderivate
|
|
DE102008038220A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
Oxadiazolderivate
|
|
CN102216309B
(zh)
|
2008-11-19 |
2014-05-07 |
沃泰克斯药物股份有限公司 |
C-met蛋白激酶的三唑并噻二唑抑制剂
|
|
WO2010059771A1
(en)
|
2008-11-20 |
2010-05-27 |
Osi Pharmaceuticals, Inc. |
Substituted pyrrolo[2,3-b]-pyridines and-pyrazines
|
|
PA8851101A1
(es)
*
|
2008-12-16 |
2010-07-27 |
Lilly Co Eli |
Compuesto amino pirazol
|
|
DE102008063667A1
(de)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
|
|
MX2011006682A
(es)
|
2008-12-22 |
2011-07-13 |
Merck Patent Gmbh |
Nuevas formas polimorficas de dihidrogeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirim idin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparacion.
|
|
DE102008062825A1
(de)
*
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
|
|
FR2941952B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
FR2941949B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
FR2941951B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
FR2941950B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
CN102388048B
(zh)
|
2009-02-10 |
2014-07-30 |
阿斯利康(瑞典)有限公司 |
三唑并[4,3-b]哒嗪衍生物及其用于前列腺癌的用途
|
|
CA2754180A1
(en)
|
2009-03-09 |
2010-09-16 |
The Regents Of The University Of California |
Substituted heterocycles and their use as allosteric modulators of nicotinic and gabaa receptors
|
|
ES2548571T3
(es)
|
2009-04-02 |
2015-10-19 |
Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii |
Derivados de imidazo[2,1-b][1,3,4]tiadiazol
|
|
EP2435444A1
(en)
|
2009-05-28 |
2012-04-04 |
Vertex Pharmaceuticals Incorporated |
Substituted pyrazole inhibitors of c-met protein kinase
|
|
JP2012528188A
(ja)
*
|
2009-05-28 |
2012-11-12 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
c−Metタンパク質キナーゼの阻害剤
|
|
DK2435443T3
(da)
*
|
2009-05-28 |
2013-10-28 |
Vertex Pharma |
Aminopyrazoltriazolothiadiazolhæmmere af c-met-proteinkinase
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
EA201200260A1
(ru)
|
2009-08-12 |
2012-09-28 |
Новартис Аг |
Гетероциклические гидразоны и их применение для лечения рака и воспаления
|
|
MX2012002179A
(es)
|
2009-08-20 |
2012-03-16 |
Novartis Ag |
Compuestos heterociclicos de oxima.
|
|
RS61281B1
(sr)
*
|
2009-12-31 |
2021-02-26 |
Hutchison Medipharma Ltd |
Sintetički intermedijer koristan u pripremi triazolopiridinskih c-met inhibitora
|
|
JP5714030B2
(ja)
|
2010-02-03 |
2015-05-07 |
インサイト コーポレーションIncyte Corporation |
C−Met阻害剤としてのイミダゾ[1,2−b][1,2,4]トリアジン
|
|
WO2011143646A1
(en)
|
2010-05-14 |
2011-11-17 |
OSI Pharmaceuticals, LLC |
Fused bicyclic kinase inhibitors
|
|
AR081039A1
(es)
|
2010-05-14 |
2012-05-30 |
Osi Pharmaceuticals Llc |
Inhibidores biciclicos fusionados de quinasa
|
|
EP3450432A1
(en)
|
2010-05-17 |
2019-03-06 |
Incozen Therapeutics Pvt. Ltd. |
Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued - 3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
|
|
US8263777B2
(en)
|
2010-05-27 |
2012-09-11 |
Vertex Pharmaceuticals Incorporated |
Aminopyrazole triazolothiadiazole inhibitor of c-Met protein kinase
|
|
JP2013532627A
(ja)
|
2010-07-01 |
2013-08-19 |
武田薬品工業株式会社 |
cMET阻害剤とHGFおよび/またはcMETに対する抗体との組み合わせ
|
|
AR085183A1
(es)
*
|
2010-07-30 |
2013-09-18 |
Lilly Co Eli |
Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
|
|
EP2710003A1
(en)
|
2011-05-16 |
2014-03-26 |
OSI Pharmaceuticals, LLC |
Fused bicyclic kinase inhibitors
|
|
GEP201706656B
(en)
|
2011-11-11 |
2017-04-25 |
Pfizer |
2-thiopyrimidinones
|
|
EP2822931B1
(en)
|
2012-03-09 |
2017-05-03 |
Inception 2, Inc. |
Triazolone compounds and uses thereof
|
|
TW201341367A
(zh)
|
2012-03-16 |
2013-10-16 |
Axikin Pharmaceuticals Inc |
3,5-二胺基吡唑激酶抑制劑
|
|
AP3908A
(en)
|
2012-03-30 |
2016-11-24 |
Rhizen Pharmaceuticals Sa |
Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases
|
|
AR092742A1
(es)
|
2012-10-02 |
2015-04-29 |
Intermune Inc |
Piridinonas antifibroticas
|
|
ES2660249T3
(es)
|
2012-12-20 |
2018-03-21 |
Inception 2, Inc. |
Compuestos de tipo triazolona y sus usos
|
|
JP2016529311A
(ja)
|
2013-09-06 |
2016-09-23 |
インセプション 2、 インコーポレイテッド |
トリアゾロン化合物類及びそれらの使用
|
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
|
AU2013402175B2
(en)
|
2013-09-30 |
2017-09-07 |
Handok Inc. |
Novel triazolopyrazine derivative and use thereof
|
|
GB201321745D0
(en)
*
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
US10233195B2
(en)
|
2014-04-02 |
2019-03-19 |
Intermune, Inc. |
Anti-fibrotic pyridinones
|
|
EP3229836B1
(en)
|
2014-12-09 |
2019-11-13 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Human monoclonal antibodies against axl
|
|
HUE049801T2
(hu)
|
2014-12-23 |
2020-10-28 |
Sma Therapeutics Inc |
3,5-diaminopirazol kináz inhibitorok
|
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
|
EP3285764B1
(en)
*
|
2015-03-31 |
2024-03-27 |
University of Vermont and State Agricultural College |
Triazolopyridazines for treating cryptosporidiosis
|
|
MA42035A
(fr)
|
2015-05-05 |
2018-03-14 |
Pfizer |
2-thiopyrimidinones
|
|
SG10201912684TA
(en)
*
|
2015-06-25 |
2020-03-30 |
Taiho Pharmaceutical Co Ltd |
Therapeutic agent for fibrosis
|
|
LT3319959T
(lt)
|
2015-07-06 |
2021-12-27 |
Alkermes, Inc. |
Histono deacetilazės hetero-halogeno inhibitoriai
|
|
US10421756B2
(en)
|
2015-07-06 |
2019-09-24 |
Rodin Therapeutics, Inc. |
Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
|
|
PE20181197A1
(es)
|
2015-10-14 |
2018-07-23 |
Bristol Myers Squibb Co |
2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
|
|
BR112018010720A8
(pt)
|
2015-12-04 |
2019-02-26 |
Bristol Myers Squibb Co |
agonistas do receptor de apelina e métodos de uso
|
|
ES2854733T3
(es)
|
2015-12-16 |
2021-09-22 |
Bristol Myers Squibb Co |
Heteroarilhidroxipirimidinonas como agonistas del receptor APJ
|
|
TWI744301B
(zh)
|
2016-03-24 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
做為apj促效劑之6-羥基-4-側氧-1,4-二氫嘧啶-5-甲醯胺
|
|
GR1009565B
(el)
*
|
2016-07-14 |
2019-08-06 |
Galenica Α.Ε. |
Νεα παραγωγα 1,2,4-τριαζολο-[3,4-b]-1,3,4-θειαδιαζολιων
|
|
ES2909086T3
(es)
|
2017-01-11 |
2022-05-05 |
Alkermes Inc |
Inhibidores bicíclicos de histona desacetilasa
|
|
MX2021007061A
(es)
|
2017-02-15 |
2022-10-07 |
Taiho Pharmaceutical Co Ltd |
Composición farmacéutica que comprende 4-(2-fluoro-4-(3-(2- fenilacetil)tioureido)fenoxi)-7-metoxi-n-metilquinolina-6-carboxa mida e hidroxipropil-b-ciclodextrina.
|
|
JP6915907B2
(ja)
*
|
2017-05-26 |
2021-08-04 |
江▲蘇▼新元素医▲薬▼科技有限公司Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. |
尿酸排泄を促進するurat1阻害剤
|
|
EP3652165B1
(en)
*
|
2017-07-12 |
2021-08-25 |
Bristol-Myers Squibb Company |
Five membered-aminoheterocyclic and 5,6-or 6,6-membered bicyclic aminoheterocyclic inhibitors of rock for the treatment of heart failure
|
|
SG11202000970WA
(en)
|
2017-08-07 |
2020-02-27 |
Rodin Therapeutics Inc |
Bicyclic inhibitors of histone deacetylase
|
|
WO2019049956A1
(ja)
|
2017-09-08 |
2019-03-14 |
大鵬薬品工業株式会社 |
抗腫瘍剤及び抗腫瘍効果増強剤
|
|
WO2019178129A1
(en)
|
2018-03-13 |
2019-09-19 |
Shire Human Genetic Therapies, Inc. |
Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
|
|
US11370803B2
(en)
|
2019-09-18 |
2022-06-28 |
Takeda Pharmaceutical Company Limited |
Heteroaryl plasma kallikrein inhibitors
|
|
PT4031547T
(pt)
|
2019-09-18 |
2024-08-27 |
Takeda Pharmaceuticals Co |
Inibidores de calicreína plasmática e utilizações dos mesmos
|
|
TR202009388A1
(tr)
*
|
2020-06-17 |
2021-12-21 |
Anadolu Ueniversitesi |
Akci̇ğer kanseri̇ tedavi̇si̇nde hedefe yöneli̇k yeni̇ tri̇azoloti̇yadi̇azi̇n türevleri̇
|
|
TR202010296A1
(tr)
|
2020-06-30 |
2022-01-21 |
Anadolu Ueniversitesi |
Akt inhibisyonu aracılığıyla a549 hücrelerinde sitotoksik ve apoptotik etki gösteren yeni triazol ve triazolotiyadiazin türevleri
|
|
JP2024506858A
(ja)
|
2021-02-02 |
2024-02-15 |
リミナル・バイオサイエンシーズ・リミテッド |
Gpr84アンタゴニストおよびその使用
|
|
KR20230153387A
(ko)
|
2021-02-02 |
2023-11-06 |
리미널 바이오사이언시스 리미티드 |
Gpr84 길항제 및 이의 용도
|
|
JP2024510504A
(ja)
*
|
2021-03-17 |
2024-03-07 |
武田薬品工業株式会社 |
血漿カリクレインの多環式インヒビター
|